CN108048347B - 鼠李糖乳杆菌、鼠李糖乳杆菌制剂及其用途 - Google Patents
鼠李糖乳杆菌、鼠李糖乳杆菌制剂及其用途 Download PDFInfo
- Publication number
- CN108048347B CN108048347B CN201711276356.8A CN201711276356A CN108048347B CN 108048347 B CN108048347 B CN 108048347B CN 201711276356 A CN201711276356 A CN 201711276356A CN 108048347 B CN108048347 B CN 108048347B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus rhamnosus
- oral
- bacteria
- oral cavity
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 107
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000002207 metabolite Substances 0.000 claims abstract description 17
- 230000003834 intracellular effect Effects 0.000 claims abstract description 8
- 238000004140 cleaning Methods 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 235000021056 liquid food Nutrition 0.000 claims abstract description 7
- 235000021055 solid food Nutrition 0.000 claims abstract description 7
- 239000000654 additive Substances 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 238000009629 microbiological culture Methods 0.000 claims abstract description 3
- 241000894006 Bacteria Species 0.000 claims description 45
- 239000000843 powder Substances 0.000 claims description 16
- 244000005700 microbiome Species 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 230000000996 additive effect Effects 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 18
- 241000194019 Streptococcus mutans Species 0.000 abstract description 16
- 239000006041 probiotic Substances 0.000 abstract description 15
- 235000018291 probiotics Nutrition 0.000 abstract description 15
- 244000000010 microbial pathogen Species 0.000 abstract description 13
- 241000605862 Porphyromonas gingivalis Species 0.000 abstract description 11
- 208000002064 Dental Plaque Diseases 0.000 abstract description 10
- 208000025157 Oral disease Diseases 0.000 abstract description 10
- 208000030194 mouth disease Diseases 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 9
- 208000002925 dental caries Diseases 0.000 abstract description 8
- 201000001245 periodontitis Diseases 0.000 abstract description 8
- 241001052560 Thallis Species 0.000 abstract description 7
- 230000000529 probiotic effect Effects 0.000 abstract description 7
- 241000605986 Fusobacterium nucleatum Species 0.000 abstract description 6
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 241000194026 Streptococcus gordonii Species 0.000 abstract description 2
- 239000006228 supernatant Substances 0.000 description 19
- 244000052616 bacterial pathogen Species 0.000 description 18
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 16
- 239000006189 buccal tablet Substances 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 14
- 230000003385 bacteriostatic effect Effects 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 238000000855 fermentation Methods 0.000 description 11
- 230000004151 fermentation Effects 0.000 description 11
- 102000016943 Muramidase Human genes 0.000 description 9
- 108010014251 Muramidase Proteins 0.000 description 9
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 9
- 239000004325 lysozyme Substances 0.000 description 9
- 229960000274 lysozyme Drugs 0.000 description 9
- 235000010335 lysozyme Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 241000194017 Streptococcus Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 229940046011 buccal tablet Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 102000016938 Catalase Human genes 0.000 description 4
- 108010053835 Catalase Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010062877 Bacteriocins Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- 241001337904 Gordonia <angiosperm> Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003239 periodontal effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000606750 Actinobacillus Species 0.000 description 2
- 241000186046 Actinomyces Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000034619 Gingival inflammation Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000004523 agglutinating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种鼠李糖乳杆菌,菌株(Lactobacillus rhamnosus)LR863,保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.14410。本发明的鼠李糖乳杆菌具有对变异链球菌、戈登链球菌、牙龈卟啉单胞菌、具核梭杆菌、伴放线放线杆菌等口腔病原微生物显著的抑菌、杀菌作用,减少牙菌斑形成和降低龋齿、牙周炎等口腔疾病发生、发展的功效。本发明的鼠李糖乳杆菌制剂可包括鼠李糖乳杆菌活菌菌体、鼠李糖乳杆菌死菌菌体、鼠李糖乳杆菌的代谢产物及胞内提取物,是一款应用广泛、效果显著的口腔益生菌制剂,可用作广泛液态食品、固态食品、胶状食品、口腔清洁用品和口腔治疗药品的添加剂。
Description
技术领域
本发明涉及微生物领域,尤其涉及一种鼠李糖乳杆菌,以及鼠李糖乳杆菌制剂,还涉及该制剂的用途。
背景技术
口腔内微生物群由700种微生物构成,存在多种病原微生物,临床常见的口腔疾病如龋齿、牙周炎和口臭等,都与致病菌或对口腔健康不利的微生物在口腔中的过量生长有关。目前预防和治疗口腔疾病多从减少变异链球菌发挥作用的角度出发,如通过使用漱口水、减少糖摄入等方式减少变异链球菌的数量,或通过机械去除牙菌斑等手段。益生菌(Probiotics)是一类对宿主有益的活性微生物的总称,能产生确切的健康功效从而改善宿主微生态平衡、发挥有益作用,因此,人们尝试使用益生菌来改善口腔环境达到防治口腔疾病的效果。
益生菌有许多令人惊奇的功效,但这些不同的功效高度依赖于“菌株的特定性”,通过大量和长期的临床研究证实,某个特定的益生菌株具有某种明确的功能但并不意味着其他同种益生菌的不同菌株也必定有同样或相似的功能,如瑞卡福抑菌喷剂能帮助修复因致病菌感染造成的生殖系统疾病,但并不能说明任何其他的同类菌株产品也有同样的功效。而且国际上对益生菌的定义通常是活的、有足够数量并对宿主有益的微生物菌种才能称之为益生菌,因此使用益生菌达到防治口腔疾病的目的,需使益生菌在口腔环境下能维持活性并具有足够数量,否则无法达到有益效果。
发明内容
为解决现有技术存在的不足,本发明提供了一种鼠李糖乳杆菌,该鼠李糖乳杆菌的活菌和死菌都具有抑制口腔致病微生物生长、杀灭口腔致病微生物的用途,能够防治牙周炎、龋齿等口腔疾病。
为实现上述目的,本发明提供的鼠李糖乳杆菌,菌株(Lactobacillus rhamnosus)LR863,已于2017年7月12日保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.14410。
根据菌株的菌落、菌体形态特征、16SrRNA序列分析及API细菌鉴定系统分析结果来确认菌株在分类学地位,发现LR863菌株为鼠李糖乳杆菌。该菌株在形态学及一般性质上的特征如下:
1、菌体或菌落形态:
菌体形态:菌体在显微镜下呈杆状。菌体成单、成对或成链,不形成芽孢,革兰氏染色阳性,无运动性,无鞭毛。
菌落形态:固体培养基上形成明显菌落,直径在0.5-1mm之间,圆形,边缘整齐,白色不透明,表面光滑湿润。
2、生理生化特征:
氧化酶阴性,接触酶阴性。
利用API 50CH试剂验证此乳酸菌种的碳水化合物代谢性能。API 50CH 试剂可用来鉴定菌株在属或种上的差异。经由分析结果确认此乳酸菌种与鼠李糖乳杆菌的碳水化合物代谢活性相同。
最适生长温度为37℃,兼性厌氧。不具有致病性,不产毒素。
作为对上述技术方案的限定,所述鼠李糖乳杆菌具有对口腔病原微生物抑菌、杀菌的用途。
作为对上述技术方案的限定,所述口腔病原微生物包括变异链球菌、戈登链球菌、牙龈卟啉单胞菌、具核梭杆菌、伴放线放线杆菌等。
作为对上述技术方案的限定,所述鼠李糖乳杆菌具有防治牙周炎的用途。
作为对上述技术方案的限定,所述鼠李糖乳杆菌具有防治龋齿的用途。
本发明的鼠李糖乳杆菌,从健康口腔志愿者的口腔中分离得到,具有产细菌素、过氧化氢的特性,能够起到广谱抗菌、杀菌作用;其菌体具有较强的凝集能力,为乳酸菌在口腔环境中与其他微生物,尤其致病微生物共凝集提供了必要的条件;还具有较强的疏水性,为口腔中粘附和定植提供了有利条件;因此该鼠李糖乳杆菌对浮游状态的变异链球菌、牙龈卟啉单胞菌等口腔致病微生物的生长有抑制作用,能有效降低戈登链球菌的数量,进而减少牙菌斑的形成,减少牙周致病菌滋生的温床,避免细菌产生的毒素对造成牙龈发炎,及牙龈下齿槽骨骨质的流失,减低牙周病发生率,在预防、减少或治疗龋齿、牙周炎的用途方面具有应用价值,还能帮助维持正常的口腔微生态菌群,保障口腔健康。
同时,本发明还提供了一种鼠李糖乳杆菌制剂,该制剂包括如上所述的鼠李糖乳杆菌活菌菌体、鼠李糖乳杆菌死菌菌体、鼠李糖乳杆菌的代谢产物及胞内提取物中的至少一种。
作为对上述技术方案的限定,所述鼠李糖乳杆菌制剂包括鼠李糖乳杆菌活菌冷冻干燥菌粉、鼠李糖乳杆菌死菌冷冻干燥菌粉、鼠李糖乳杆菌代谢产物冷冻干燥粉末、鼠李糖乳杆菌活菌及代谢产物冷冻干燥菌粉、鼠李糖乳杆菌死菌及代谢产物冷冻干燥菌粉。
通常益生菌制剂需为活菌并在足够数量前提下才能发挥有益效果,本发明的鼠李糖乳杆菌,不仅其活菌具有对口腔病原微生物抑菌、杀菌作用,减少牙菌斑形成和降低龋齿、牙周炎等口腔疾病发生、发展的功效,其死菌同样具有抑菌、杀菌作用和防治口腔疾病的功效。分别由鼠李糖乳杆菌活菌菌体、鼠李糖乳杆菌死菌菌体、鼠李糖乳杆菌的代谢产物及胞内提取物中任一种或混合物形成的益生菌制剂,不受活菌数量及活性的限制,更利于在宿主体内发挥作用,是一款应用广泛、效果显著的口腔益生菌制剂。
同时,本发明提供了上述鼠李糖乳杆菌制剂的用途,可用作液态食品、固态食品、胶状食品、口腔清洁用品和口腔治疗药品的添加剂。
基于本发明鼠李糖乳杆菌的活菌、死菌均具有抑菌、杀菌作用和防治口腔疾病功效的优势,其使用形式广泛,可广泛应用于液态食品,如果汁、酸奶、茶饮料等;固态食品,如口含片、固体饮料、糖果、巧克力、饼干等;胶状食品,如果冻、口香糖、优格、布丁等;口腔清洁用品,如牙膏、漱口水等;和口腔治疗药品,如口含片、软膏等。
综上所述,本发明的鼠李糖乳杆菌,菌株(Lactobacillus rhamnosus)LR863,保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.14410,具有对变异链球菌、戈登链球菌、牙龈卟啉单胞菌、具核梭杆菌、伴放线放线杆菌等口腔病原微生物显著的抑菌、杀菌作用,和减少牙菌斑形成,降低龋齿、牙周炎等口腔疾病发生、发展的功效。本发明的鼠李糖乳杆菌制剂由活菌菌体、死菌菌体、代谢产物及胞内提取物中的至少一种制成,不受活菌数量及活性的限制,更利于在宿主体内发挥作用,是一款应用广泛、效果显著的口腔益生菌制剂,可用作广泛液态食品、固态食品、胶状食品、口腔清洁用品和口腔治疗药品的添加剂。
附图说明
图1:本发明实施例所述鼠李糖乳杆菌LR863活菌对五种口腔致病菌的共凝集能力;
图2:本发明实施例所述鼠李糖乳杆菌LR863死菌对五种口腔致病菌的共凝集能力。
具体实施方式
下面将结合实施例,对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例一
本实施例涉及本发明鼠李糖乳杆菌菌株的分离、纯培养和鉴定。
添加碳酸钙的MRS固体培养基:葡萄糖20.0g;蛋白胨10.0g;牛肉浸粉 10.0g;酵母浸粉5.0g;柠檬酸氢二铵2.0g;乙酸钠5.0g;磷酸氢二钾2.0g;硫酸镁0.58g;硫酸锰0.25g;吐温80 1.0mL;蒸馏水1000mL;调节pH6.2-6.4;再添加琼脂15.0g;碳酸钙5.0g,115℃灭菌20min。
采集健康口腔志愿者的唾液和牙菌斑样本,加入无菌生理盐水制成1:10 的样品匀液,充分震荡均匀,8000rpm离心5min,收集沉淀,加入适量生理盐水将沉淀充分混匀,将混匀后的悬浮液涂布于添加碳酸钙的MRS固体培养基中,37℃厌氧培养48h,挑选周围形成溶钙圈的典型菌落,进一步划线纯化,挑选革兰氏染色镜检为阳性、接触酶实验阴性的菌株。采用琼脂扩散法进一步筛选出能够抑制变异链球菌和戈登链球菌的乳酸菌。
将分离得到的一株抑菌活性最佳的乳酸菌命名为LR863。通过生理生化鉴定,同时采用PCR扩增该菌16S rRNA序列,进行比对分析,结果显示该序列与NCBI数据库中鼠李糖乳杆菌的同源性达99%,因此将该菌鉴定为鼠李糖乳杆菌,命名为鼠李糖乳杆菌LR863(Lactobacillus rhamnosus LR863),并于2017年7月12日保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏中心地址为北京市朝阳区北辰西路1号院3号中国科学院微生物研究所,保藏编号为CGMCC No.14410。
实施例二
本实施例涉及本发明鼠李糖乳杆菌菌株的功能性鉴定。
实施例2.1
菌株(Lactobacillus rhamnosus)LR863产过氧化氢能力检测。
检测方法:将该菌株接种到MRS培养基中37℃静置培养,将发酵液4℃, 8000rpm离心20min收集上清液,用过氧化氢试剂盒检测上清液中过氧化氢的含量。
检测结果:菌株LR863培养18h、24h、30h产过氧化氢量分别为0.161g/L、 0.104g/L和0.073g/L,证明该菌株具有产过氧化氢的能力。
实施例2.2
菌株(Lactobacillus rhamnosus)LR863的代谢产物对口腔致病菌抑菌能力检测。
(一)检测方法:
本实例中所用的口腔致病菌包括:
变异链球菌作为龋齿致病菌使用BHI培养基,37℃厌氧培养18h;
戈登链球菌作为牙菌斑生物膜基础菌株使用BHI培养基,37℃厌氧培养 18h;
牙龈卟啉单胞菌、具核梭杆菌、伴放线放线杆菌作为牙周致病菌,使用 TSA培养基添加有5%脱纤维养血、0.1%维生素K1,37℃厌氧培养5-7天。
将鼠李糖乳杆菌LR863按3%接种量接于MRS培养基中,37℃静置培养 24h,发酵液经4℃,8000rpm离心20min,收集上清液并用0.22μm微孔滤膜过滤得到LR863无细胞发酵上清液。
分别调节变异链球菌和戈登链球菌的每种菌液浓度约为1×108cfu/mL,取 100μL致病菌菌液与10mL固体BHI培养基混匀,倒入无菌培养皿中,采用打孔法,每孔加入100μL乳酸菌发酵上清液,37℃静置培养20-24h,测量抑菌圈大小。
分别调节牙龈卟啉单胞菌、具核梭杆菌、伴放线放线杆菌的每种菌液浓度约为1×108cfu/mL,取100μL致病菌菌液均匀涂布于20mL固体TSA培养基上,采用牛津杯法,每个牛津杯中加入100μL乳酸菌发酵上清液,37℃静置培养5-7天,测量抑菌圈大小。
检测结果:如表1所示;
表1鼠李糖乳杆菌LR863对5株口腔致病菌的抑菌能力
由上表可见,鼠李糖乳杆菌LR863及其代谢产物对5株口腔致病菌具有较强的抑制作用。
(二)、检测方法:对鼠李糖乳杆菌LR863抑菌物质的初步探究实验。
将鼠李糖乳杆菌LR863发酵上清液用1.0mol/L的氢氧化钠调节pH值至 pH5.5过滤除菌,并以pH5.5的MRS培养基和没有调节pH值的发酵上清液过滤除菌作为对照,将变异链球菌作为指示菌检测抑菌活性,以此来排除酸性物质对抑菌活性的影响。取四份鼠李糖乳杆菌LR863发酵上清液,分别调至各蛋白酶最适pH值,即调节pH值分别为pH7.0,pH7.0,pH2.0,pH7.0,然后分别添加过氧化氢酶、胰蛋白酶、胃蛋白酶和蛋白酶K,使四种蛋白酶终浓度均为1mg/mL,37℃水浴3h,将上清液pH值调制pH5.5,过滤除菌。并以相同酶处理的MRS培养基作为空白对照,同时将未经过酶处理的pH5.5 发酵上清液作为对照。以此来探究蛋白酶对抑菌物质活性的影响。
检测结果:如表2所示;
表2不同处理对鼠李糖乳杆菌LR863代谢产物中有效抑菌物质的影响
从表2可以看出抑菌物质的抑菌活性具有pH依赖性,将发酵上清液的 pH调至pH5.5后其抑菌活性下降,通过调节发酵上清液pH值排除酸类物质后仍具有抑菌活性表明上清液中还含有其他的抑菌活性成分。发酵上清液经过氧化氢酶处理后的抑菌结果可以看出,鼠李糖乳杆菌LR863代谢产物中含有过氧化氢。经胰蛋白酶、胃蛋白酶和蛋白酶K处理后的发酵上清液抑菌活性下降,表明鼠李糖乳杆菌LR863代谢产物中可能含有蛋白类或多肽类的细菌素。
实施例2.3
菌株(Lactobacillus rhamnosus)LR863的与致病菌共凝集能力检测。
检测方法:将鼠李糖乳杆菌LR863和致病菌分别5000rpm离心15min,收集菌体用pH7.0的PBS洗涤菌体,调节两种菌液浓度为OD600=0.6±0.05,将两种菌液等体积混合,充分震荡2min,37℃静置,每隔1h于相同液面高度贴壁缓慢吸取上清1mL,测定不同时间的OD600吸光值,并按以下公式计算交互凝集率:
其中Ax=0h鼠李糖乳杆菌的吸光值,Ay=0h致病菌的吸光值,Amix=th后混合的吸光值。
检测结果:见图1的LR863活菌对五种口腔致病菌的共凝集能力趋势图,及图2的LR863死菌对五种口腔致病菌的共凝集能力趋势图所示。
实施例2.4
菌株(Lactobacillus rhamnosus)LR863的对溶菌酶耐受性检测。
检测方法:取1mL鼠李糖乳杆菌菌液(107cfu/mL),加至20mL冷却至 50℃的固体MRS培养基中混合均匀,倒入灭菌培养皿中,待培养基凝固后放置牛津杯,将浓度分别为0.05mg/mL、0.1mg/mL、0.2mg/mL、0.4mg/mL、 0.6mg/mL、0.8mg/mL、1.0mg/mL、2.0mg/mL溶菌酶溶液100μL加入牛津杯中,37℃培养24h,根据抑菌圈的情况分析鼠李糖乳杆菌对溶菌酶的耐受性,从而判断溶菌酶对鼠李糖乳杆菌存活率的影响,结果见表3所示;
表3溶菌酶对鼠李糖乳杆菌LR863的影响
由表3可以看出,浓度为0-2.0mg/mL溶菌酶不影响鼠李糖乳杆菌LR863 的生长,表明其对溶菌酶具有较强的耐受性,口腔中溶菌酶浓度约为 1-57μg/mL,所以鼠李糖乳杆菌LR863在口腔中的存活不受溶菌酶影响。
实施例2.5
菌株(Lactobacillus rhamnosus)LR863的粘附性检测
检测方法:菌株LR863发酵液离心5000r/min,10min,收集菌体,用PBS (pH6.8)洗涤离心一遍,用PBS(pH6.8)重悬菌体,调整菌液浓度在560nm 波长下,吸光值约为1.000,记为A0。取4mL菌悬液分别与0.8mL二甲苯、乙酸乙酯、氯仿混合,振荡30s、静置10s,振荡30s、静置20min,待两相分层后,吸取水相测定在560nm波长下的吸光值,记为A,并按以下公式计算疏水率:
疏水率(CSH%)=(1-A/A0)×100%
每组实验做3个平行,取平均值。
检测结果:如表4所示;
表4鼠李糖乳杆菌LR863的粘附性结果
根据疏水率标准:疏水率大于50%为高疏水性,介于20%和50%为中度疏水,小于20%为非疏水。由表4结果可见,鼠李糖乳杆菌LR863具有良好的疏水性,表面疏水性与粘附作用呈正相关,因而其在口腔中具有相对较高的粘附能力。
实施例三
本实施例涉及菌株(Lactobacillus rhamnosus)LR863的临床应用。
菌株(Lactobacillus rhamnosus)LR863的应用形式广泛,可用作液态食品、固态食品、胶状食品、口腔清洁用品和口腔治疗药品等的添加剂。
以菌株(Lactobacillus rhamnosus)LR863的口含片临床试验为例。
口含片的制备:由鼠李糖乳杆菌LR863冻干菌粉、山梨糖醇、全脂奶粉、硬脂酸镁等组分制成口含片,活菌口含片中鼠李糖乳杆菌LR863的活菌数达到1×108cfu/g;死菌口含片中鼠李糖乳杆菌LR863的死菌数达到1×108个/g。对照组口含片将鼠李糖乳杆菌LR863冻干菌粉用等量全脂奶粉代替。
鼠李糖乳杆菌LR863冻干菌粉的制备,按常规微生物培养方法于37℃静置培养20~30h,采用补碱工艺培养过程保持pH值一定,保证鼠李糖乳杆菌生长的最适环境。通过离心方式收集鼠李糖乳杆菌活菌菌体;其代谢产物和培养浓缩液通过离心鼠李糖乳杆菌发酵液的方式收集;鼠李糖乳杆菌的胞内产物通过物理方法破壁后进行收集;死菌菌体由活菌菌体以物理热灭活方式制成。
检测方法:采用双盲试验将25名20-50岁的受试者随机分成三组,第一组和第二组每日三餐后30min,分别食用LR863活菌口含片、LR863死菌口含片,第三组食用未添加LR863的空白对照口含片,连续食用两周,监测受试者口腔内变异链球菌和牙龈卟啉单胞菌的数量变化。
其中,口腔内变异链球菌和牙龈卟啉单胞菌采用荧光定量PCR进行定量分析。受试者的口腔样品采集方法为,在试吃开始前用牙线采集受试者牙菌斑样本,作为上述实验的前值,试吃2周后,同样用牙线收集相同位置的牙菌斑样本,并通过荧光定量PCR进行定量分析评价上述实验效果。受试者服用口含片后口腔中变异链球菌和牙龈卟啉单胞菌数量较试吃前显著性下降即判定为有效,受试者在服用口含片后口腔中变异链球菌和牙龈卟啉单胞菌数量维持不变或致病菌数量增加则判定为无效。
每组有效率%=该组有效受试者人数/该组总人数×100%
检测结果:如表5所示;
表5服用2周后每组受试人群有效率
由表5结果可见,本发明的鼠李糖乳杆菌LR863,其活菌制剂、死菌制剂的临床应用有效率都十分显著,具有推广应用价值。
综上所述,本发明的鼠李糖乳杆菌,菌株(Lactobacillus rhamnosus)LR863,保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.14410,具有产细菌素、过氧化氢的特性,能够起到广谱抗菌、杀菌作用;其菌体具有较强的凝集能力,为乳酸菌在口腔环境中与其他微生物,尤其致病微生物共凝集提供了必要的条件;还具有较强的疏水性,为口腔中粘附和定植提供了有利条件;因此该鼠李糖乳杆菌对浮游状态的变异链球菌、戈登链球菌、牙龈卟啉单胞菌、具核梭杆菌、伴放线放线杆菌等口腔致病微生物的生长有抑制作用,能有效降低变异链球菌的数量,进而减少牙菌斑的形成,减少牙周致病菌滋生的温床,避免细菌产生的毒素对造成牙龈发炎,及牙龈下齿槽骨骨质的流失,减低牙周病发生率,在预防、减少或治疗龋齿、牙周炎的用途方面具有应用价值,还能帮助维持正常的口腔微生态菌群,保障口腔健康。本发明的鼠李糖乳杆菌制剂由活菌菌体、死菌菌体、代谢产物及胞内提取物中的至少一种制成,不受活菌数量及活性的限制,更利于在宿主体内发挥作用,是一款应用广泛、效果显著的口腔益生菌制剂,可广泛用作液态食品、固态食品、胶状食品、口腔清洁用品和口腔治疗药品的添加剂。
Claims (4)
1.一种鼠李糖乳杆菌,其特征在于:所述鼠李糖乳杆菌菌株(Lactobacillusrhamnosus)LR863,保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.14410。
2.一种鼠李糖乳杆菌制剂,其特征在于:包括如权利要求1所述的鼠李糖乳杆菌活菌菌体、鼠李糖乳杆菌死菌菌体、鼠李糖乳杆菌的代谢产物及胞内提取物中的至少一种。
3.根据权利要求2所述的鼠李糖乳杆菌制剂,其特征在于:所述鼠李糖乳杆菌制剂包括鼠李糖乳杆菌活菌冷冻干燥菌粉、鼠李糖乳杆菌死菌冷冻干燥菌粉、鼠李糖乳杆菌代谢产物冷冻干燥粉末、鼠李糖乳杆菌活菌及代谢产物冷冻干燥菌粉、鼠李糖乳杆菌死菌及代谢产物冷冻干燥菌粉。
4.一种如权利要求2所述的鼠李糖乳杆菌制剂的用途,其特征在于:用作液态食品、固态食品、胶状食品、口腔清洁用品和口腔治疗药品的添加剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711276356.8A CN108048347B (zh) | 2017-12-06 | 2017-12-06 | 鼠李糖乳杆菌、鼠李糖乳杆菌制剂及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711276356.8A CN108048347B (zh) | 2017-12-06 | 2017-12-06 | 鼠李糖乳杆菌、鼠李糖乳杆菌制剂及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108048347A CN108048347A (zh) | 2018-05-18 |
CN108048347B true CN108048347B (zh) | 2020-06-02 |
Family
ID=62122587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711276356.8A Active CN108048347B (zh) | 2017-12-06 | 2017-12-06 | 鼠李糖乳杆菌、鼠李糖乳杆菌制剂及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108048347B (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109401994A (zh) * | 2018-08-27 | 2019-03-01 | 南昌大学 | 一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用 |
CN109566825A (zh) * | 2018-10-10 | 2019-04-05 | 桂林三金药业股份有限公司 | 一种含有口腔益生菌的压片糖果及其制备方法 |
CN110172420B (zh) * | 2019-05-15 | 2022-03-01 | 福建省农业科学院农业工程技术研究所 | 一株鼠李糖乳杆菌及其应用 |
CN110115292A (zh) * | 2019-06-11 | 2019-08-13 | 河北农业大学 | 一种预防龋齿的益生菌奶片及其制备方法 |
CN111518713B (zh) * | 2019-09-27 | 2021-09-28 | 江南大学 | 一株能够预防和/或治疗龋齿的鼠李糖乳杆菌及其应用 |
CN111202709A (zh) * | 2019-12-11 | 2020-05-29 | 河北一然生物科技有限公司 | 一种能够抑制痤疮丙酸杆菌的乳酸菌面膜及制备方法 |
CN111363704A (zh) * | 2019-12-12 | 2020-07-03 | 石家庄君乐宝乳业有限公司 | 有益口腔健康的鼠李糖乳杆菌x253、其分离纯化方法及应用 |
KR102217518B1 (ko) | 2020-08-18 | 2021-02-19 | 주식회사 메디오젠 | 치주염 예방 또는 치료용 유산균 및 그의 용도 |
KR102217525B1 (ko) | 2020-08-18 | 2021-02-19 | 주식회사 메디오젠 | 치주염 예방 또는 치료용 유산균 및 그의 용도 |
CN112746034B (zh) * | 2020-09-14 | 2022-07-29 | 河北一然生物科技股份有限公司 | 一种协同抑制幽门螺旋杆菌的鼠李糖乳杆菌lr863和鼠李糖乳杆菌lr519及其应用 |
CN113046258B (zh) * | 2020-10-09 | 2023-04-28 | 江南大学 | 一株能够预防和/或治疗牙周炎的鼠李糖乳杆菌及其应用 |
CN112442463A (zh) * | 2020-11-25 | 2021-03-05 | 北京科拓恒通生物技术股份有限公司 | 鼠李糖乳杆菌Probio-M9及其制剂用于制备延长寿命制品的应用 |
CN112608864B (zh) * | 2020-12-21 | 2021-08-24 | 江南大学 | 一株能够预防和/或治疗牙周炎的发酵乳杆菌及其应用 |
CN114712298A (zh) * | 2022-03-28 | 2022-07-08 | 桂龙药业(安徽)有限公司 | 一种促进口腔健康的益生元和后生元组合物及其应用 |
CN114806930B (zh) * | 2022-03-31 | 2022-11-22 | 青岛东海药业有限公司 | 一种益生菌组合物及其应用 |
CN115153026B (zh) * | 2022-04-13 | 2024-01-26 | 微康益生菌(苏州)股份有限公司 | 鼠李糖乳杆菌菌株LRa05在制备抑制幽门螺杆菌和/或变异链球菌制品方面的用途 |
CN115317522A (zh) * | 2022-07-22 | 2022-11-11 | 内蒙古科拓生物有限公司 | 一株鼠李糖乳杆菌r7970在制备病原菌抑制产品中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102470151A (zh) * | 2009-07-16 | 2012-05-23 | 国立大学法人广岛大学 | 口腔内疾病的预防、改善或治疗剂 |
CN103748220A (zh) * | 2011-02-10 | 2014-04-23 | 国立大学法人广岛大学 | 来源于鼠李糖乳杆菌的细菌素 |
CN103937708A (zh) * | 2014-03-24 | 2014-07-23 | 华东理工大学 | 鼠李糖乳杆菌及其应用 |
MD996Z (ro) * | 2015-04-01 | 2016-08-31 | ОП ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ И ФАРМАЦЕВТИЧЕСКИЙ УНИВЕРСИТЕТ им. НИКОЛАЯ ТЕСТЕМИЦАНУ РЕСПУБЛИКИ МОЛДОВА | Metodă de profilaxie a cariei dentare la copii cu dizabilităţi intelectuale |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040101495A1 (en) * | 2002-11-27 | 2004-05-27 | Leena Nase | Method for improving dental health |
-
2017
- 2017-12-06 CN CN201711276356.8A patent/CN108048347B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102470151A (zh) * | 2009-07-16 | 2012-05-23 | 国立大学法人广岛大学 | 口腔内疾病的预防、改善或治疗剂 |
CN103748220A (zh) * | 2011-02-10 | 2014-04-23 | 国立大学法人广岛大学 | 来源于鼠李糖乳杆菌的细菌素 |
CN103937708A (zh) * | 2014-03-24 | 2014-07-23 | 华东理工大学 | 鼠李糖乳杆菌及其应用 |
MD996Z (ro) * | 2015-04-01 | 2016-08-31 | ОП ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ И ФАРМАЦЕВТИЧЕСКИЙ УНИВЕРСИТЕТ им. НИКОЛАЯ ТЕСТЕМИЦАНУ РЕСПУБЛИКИ МОЛДОВА | Metodă de profilaxie a cariei dentare la copii cu dizabilităţi intelectuale |
Also Published As
Publication number | Publication date |
---|---|
CN108048347A (zh) | 2018-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108048347B (zh) | 鼠李糖乳杆菌、鼠李糖乳杆菌制剂及其用途 | |
CA2833937C (en) | Lactobacillus strains, compositions containing them and use of the strains to prevent or treat conditions caused by streptococcus pyogenes | |
Stamatova et al. | Probiotics: health benefits in the mouth. | |
KR100386144B1 (ko) | 헬리코박터 파일로리 (Helicobacterpylori)제균성 식음료 제품 | |
AU2003206479B2 (en) | Antimicrobial composition | |
CN1860219B (zh) | 乳酸杆菌在减少龋齿和细菌引发龋齿中的用途 | |
US20080063666A1 (en) | New lactic bacteria useful as probiotics | |
EP1840205B1 (en) | Bifidobacterium lactis 668 strain used as a component for food products, starters, medicinal and cosmetic agents | |
JP6033290B2 (ja) | チャノキ葉から分離した新規なラクトバチルス・プランタラム | |
KR102065580B1 (ko) | 항균 활성과 프로바이오틱스 특성을 갖는 락토바실러스 브레비스 scml 432 균주 및 이의 용도 | |
US20040101495A1 (en) | Method for improving dental health | |
EP4245841A1 (en) | Novel use of bifidobacterium lactis bl-99 in fighting aging and improving innate immunity | |
FI113057B (fi) | Menetelmä hiivojen kasvun estämiseksi | |
JP4469792B2 (ja) | 口腔内疾患予防用及び/又は治療用の発酵乳、並びに口臭予防用及び/又は抑制用の発酵乳 | |
KR20220004865A (ko) | 프로바이오틱스 관련 효소 분비능, 항산화 활성, 담즙산염 분해 활성, 항균 활성이 있고, 유해효소 및 유해대사산물을 생성하지 않는 락토바실러스 브레비스 srcm101607 균주 및 이의 용도 | |
KR101024950B1 (ko) | 메주로부터 분리된 바실러스 폴리퍼멘티쿠스 및 이를 포함하는 항진균 조성물 | |
JPWO2016194692A1 (ja) | 抗う蝕剤及び抗う蝕用組成物 | |
CN107410479B (zh) | 一种发酵乳及其制备方法 | |
TW202007401A (zh) | 一種乳酸菌組合物用於抑制胃幽門螺旋桿菌引發之胃炎及其用途 | |
BG66485B1 (bg) | Щам lactobacillus delbrueckii subsp. bulgaricus с широк спектър на приложение | |
CN113234613A (zh) | 鼠李糖乳杆菌在预防牙周病产品中的应用 | |
US20220118032A1 (en) | Fructophilic lactic acid producing bacteria | |
Mao et al. | Cariogenicity of mutants of Streptococcus mutans | |
KR20240139752A (ko) | 페디오코커스 이노피나투스 K30 (Pediococcus inopinatus K30) 균주 또는 이의 배양액을 유효성분으로 포함하는 구취 및 치태 형성의 억제, 예방 및 개선용 조성물 | |
KR20240001770A (ko) | β-갈락토시다제 분비능 및 담즙산염 분해 활성을 가지며, 프로바이오틱스 특성을 보유한 락토바실러스 브레비스 SRCM 101610 균주 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 050000 No.16, East bangxiu Road, North Zone, Zhengding high tech Industrial Development Zone, Zhengding District, China (Hebei) pilot Free Trade Zone, Shijiazhuang City, Hebei Province Patentee after: Hebei Yiran Biotechnology Co.,Ltd. Address before: 050000 No. 16, bangxiu East Road, North District, high tech Industrial Development Zone, Shijiazhuang City, Hebei Province Patentee before: HEBEI INATURAL BIOTECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address |